Sponsor:
Mirati Therapeutics Inc.
Code:
NCT05609578
Conditions
Advanced NSCLC
Metastatic Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Adagrasib oral dose of 400 mg twice daily tablets
Pembrolizumab
Chemotherapy: Pemetrexed
Cisplatin/Carboplatin
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-12-10. This information was provided to ClinicalTrials.gov by Mirati Therapeutics Inc. on 2025-08-17.